SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, EAR, HYZN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Hyzon Motors Inc. (HYZN, HYZNW) f/k/a Decarbonization Plus Acquisition Corporation (DCRB, DCRBU, DCRBW)
Class Period: 2/9/2021 - 9/27/2021
Lead Plaintiff Motion Deadline: November 29, 2021
SECURITIES FRAUD
To learn more, visit https://claimsfiler.com/cases/nasdaq-hyzn/

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

Eargo, Inc. (EAR)
Class Period: 2/25/2021 - 9/22/2021
Lead Plaintiff Motion Deadline: December 6, 2021
SECURITIES FRAUD
To learn more, visit https://claimsfiler.com/cases/nasdaq-ear/

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact us toll-free (844) 367-9658 or visit the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Cleo Diagnostics (COV:AU) has announced The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial

Download the PDF here.

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight

MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024 to discuss data from the 52-week, Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Seaweed Consultancy Renewed – Focus on Blockchain, Carbon Credits and AI to Drive R&D Program

The Board of BPH Global Ltd (ASX: BP8) (Company), is pleased to advise the re-appointment of Gaia Mariculture Pte Ltd (Gaia Mariculture) as the manager of the Company’s research and development programs (R&D Programs). Pursuant to the renewed consulting agreement, the Company’s wholly owned, Singapore-based subsidiary Stemcell United Pte Ltd (BP8 Singapore) has engaged Gaia Mariculture as a to manage the BP8 Group’s R&D Programs (Consulting Agreement).

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less

Latest Press Releases

Related News

×